Roche to start new Elevidys study following setback in Europe [Yahoo! Finance]
Sarepta Therapeutics, Inc. (SRPT)
Last sarepta therapeutics, inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investorrelations.sarepta.com/events-and-presentations
Company Research
Source: Yahoo! Finance
Roche is taking another chance on an embattled gene therapy for Duchenne muscular dystrophy, announcing on Thursday a new trial that could support a reworked approval submission in Europe. Roche owns rights outside the U.S. to Elevidys, which was developed by Sarepta Therapeutics and is approved for use in nine countries as a treatment for certain Duchenne patients who can still walk. Europe's main drug regulator, however, issued a negative opinion on Elevidys last year. It noted how testing didn't show a meaningful benefit on motor function and that the therapy's principal biological effect — producing a miniature version of a muscle-protecting protein — couldn't be linked to a positive impact. That setback was one of several in 2025 for Elevidys. The treatment was the first of its kind to win a regulatory approval and the culmination of years of scientific research . But clearance in the U.S. was based on mixed study results that cast doubt on its benefits. Last summer, it was
Show less
Read more
Impact Snapshot
Event Time:
SRPT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SRPT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SRPT alerts
High impacting Sarepta Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SRPT
News
- Sarepta Therapeutics (SRPT) had its "sell" rating reaffirmed by HC Wainwright. They now have a $5.00 price target on the stock.MarketBeat
- Sarepta Therapeutics (SRPT) had its price target raised by Royal Bank Of Canada from $18.00 to $19.00. They now have a "sector perform" rating on the stock.MarketBeat
- Sarepta Therapeutics (SRPT) had its price target raised by Wedbush from $29.00 to $35.00. They now have an "outperform" rating on the stock.MarketBeat
- Sarepta Therapeutics (SRPT) had its price target raised by Deutsche Bank Aktiengesellschaft from $12.00 to $14.00. They now have a "sell" rating on the stock.MarketBeat
- Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
SRPT
Earnings
- 2/25/26 - Miss
SRPT
Sec Filings
- 3/27/26 - Form SCHEDULE
- 3/13/26 - Form 4
- 3/13/26 - Form 4
- SRPT's page on the SEC website